Müschen Named Inaugural Director of Center of Molecular and Cellular Oncology at Yale Cancer Center and Yale School of Medicine

Markus Müschen, MD, PhD, has been named the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center (YCC) and Smilow Cancer Hospital. Müschen will also be appointed Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology at Yale School of Medicine.

“As an innovative and highly productive physician-scientist, Dr. Müschen’s leadership experience and mentorship will be a tremendous asset for Yale Cancer Center as we continue to expand our efforts in cancer research and hematological malignancies,” said Charles Fuchs, MD, MPH, director of YCC and physician-in-chief at Smilow Cancer Hospital.

Müschen joins Yale from City of Hope Comprehensive Cancer Center where he currently is the Associate Director of Basic Science and Professor and Chair of the Department of Systems Biology. Müschen is a Howard Hughes Medical Institute Faculty Scholar, a National Cancer Institute Outstanding Investigator Award (R35) recipient, and formerly a scholar of the Leukemia & Lymphoma Society, a senior investigator of the Wellcome Trust at the University of Cambridge (UK), and the Sir Alexander Haddow Professor of the Institute for Cancer Research in London.

Over the past 10 years, Müschen has developed a multidisciplinary research program to study oncogenic signaling and clonal evolution in B cell malignancies. In addition, his research has been addressing fundamental questions in immunobiology and immunotherapy and the development of new approaches to CAR T-Cell therapy.

Previously, Müschen trained in Hematology-Oncology at University of Cologne Medical Center in Germany, where he also completed post-doctoral studies in Immunology at their Institute for Genetics. He graduated from Heinrich-Heine-Universitat in Düsseldorf, Germany. From 2009 to 2016, Müschen was a tenured professor of Laboratory Medicine, Pathology, and Medicine at the University of California San Francisco (UCSF) and served as program leader of the Hematological Malignancies Program of the UCSF Helen Diller Comprehensive Cancer Center.